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The peroxisome proliferator-activated receptors (PPARs) are the transcriptional 
regulators of glucose, lipids and cholesterol metabolisms. It has been established that 
PPAR-γ is the receptor for thiazolidinediones (TZDs) class of type II anti-diabetic drugs. 
These compounds act as agonists of PPAR-γ. They may delay the development of type II 
diabetes in individuals at high risk of developing the condition, and have been shown to 
have potentially beneficial effects on cardiovascular risk factors. PPAR-γ receptor 
activation by TZDs improves insulin sensitivity by promoting fatty acid uptake into 
adipose tissue, increasing production of adiponectin (responsible for glucose regulation 
and fatty acid metabolism) and reducing levels of inflammatory mediators such as tumor 
necrosis factor-alpha (TNF-alpha), plasminogen activator inhibitor-1(PAI-1) and 
interleukin-6 (IL-6). Our goal is to take advantage of the mode of binding of known 
PPAR-γ agonists, such as Rosiglitazone to PPAR-γ to rationally design novel agonists of 
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PPAR-γ. Our long-term objective is to generate new and potent PPAR-γ agonists that 
could be used to treat diabetes. To achieve our goal the study was divided into five specific 
aims, including: Aim 1. Expression and purification of PPAR-γ ligand binding domain 
(LBD). Aim 2. Molecular modeling to design PPAR-γ receptor modulators. Aim 3. 
Synthesis of potential PPAR-γ receptor modulators. Aim 4. Functional studies to 
determine the binding affinity of PPAR-γ receptor modulators. Aim 5. Structural studies of 
PPAR-γ LBD in complex with PPAR-γ receptor modulators.   
We expressed the His-tagged PPAR-γ LBD protein in Rosetta DE3 cells, and used a 
one step affinity chromatography (Ni-NTA column) to obtain a significant yield of pure 
protein. Using the structural features and the known binding mode of Rosiglitazone to 
PPAR-γ LBD as a starting point, two classes of compounds (type-I and type-II 
compounds) were designed as potential PPAR-γ agonists. These novel compounds were 
rationalized to improve on the binding modes of Rosiglitazone via additional hydrogen-
bonding and/or hydrophobic interactions to the protein. Five type-I and II compounds were 
synthesized and tested against PPAR-γ receptor for binding affinity, using fluorescent 
polarization assay. The IC-50 value of the most potent compound (compound B) was 
found to be ~ 7-fold lower than Rosiglitazone, significantly lower than the expected value. 
It seems that unlike Rosiglitazone which has free rotatable thiazolidinedione ring that can 
make optimal interactions with His323 and His449 (two critical residues that are important 
for binding affinity), the thiazolidinedione ring in our compounds are fixed in one position 
that may not lead to optimal contact with the protein. We are currently synthesizing 
analogs of our compounds with rotatable thiazolidinedione ring for further studies. X-ray 
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crystallographic study has been initiated to determine the binding modes of our compounds 
with PPAR-γ LBD which would allow for structural modifications for improving existing 
interactions and/or formation of new favorable interactions that could lead to higher 
affinity and potency. We have also initiated testing of these compounds to determine their 
PPAR-γ agonistic effects. 
 
  1 
 
 
{CHAPTER I Introduction} 
 
 
1. Nuclear Receptor 
Nuclear receptors (NR) are a class of proteins found within the interior of cells that 
regulate the expression of specific genes thereby controlling the development, 
homeostasis, and metabolism of the organism. These receptors are soluble proteins that can 
bind to specific DNA regulatory elements (response elements or REs) and act as cell type 
and promoter-specific regulators of transcription.1, 2 In contrasts to other transcription 
factors, the activity of nuclear receptors can be modulated by binding to the corresponding 
ligands, which are small lipophilic molecules that easily penetrate biological membranes. 
However, ligands for some of these nuclear receptors have not yet been identified. Nuclear 
receptors have been implicated in many physiological processes, such as cancer, diabetes, 
rheumatoid arthritis, asthma or hormone resistance syndromes.3  As discussed in more 
detail below, nuclear receptors may be classified either according to mechanism or 
homology.4 
In general, nuclear receptors act as homo- and heterodimers by binding to REs 
consisting of two copies of PuGGTCA core sequence. Many promoters whose 
transcription was shown to be nuclear receptor-dependent have been reported to contain 
nuclear receptor REs. There are also  a great number of promoter and other gene regulatory 
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elements lacking REs but regulated by nuclear receptors through DNA-independent 
protein-mediated transcriptional control.5 By virtue of this ligand-dependent activity, the 
nuclear hormone receptors serve as an interface between cellular or the whole body 
environment and our genome. The elucidation of the full length sequence of the first two 
founding members of the family, the human glucocorticoid receptor (GR) and estrogen 
receptor α (ERα) (cloned in 1985 and 1986, respectively) revealed a common domain 
structure as well as homology to the viral oncogene “v-erbA”, suggesting the existence of a 
receptor protein family.6 Also in 1986, the cellular homologue of v-erb was discovered to 
be a receptor for thyroid hormone, indicating that ligands for the NRs are not limited to 
steroid hormones. Following, receptors for mineralocorticoid, progesterone, androgen and 
fat-soluble vitamins A and D were cloned, revealing extensive sequence similarity among 
these lipophilic hormone receptors.7 Availability of genomic sequence information reveals 
that humans encode 48 NR family members and mice encode 49 NR family members.  
During the last two decades, remarkable progress has been made toward the 
understanding of nuclear receptors in animal physiology, due to technological 
advancement in molecular genetics, genome wide target gene identification, single 
nucleotide polymorphism identification, and high throughput ligand identification. The 
notion that NRs integrate complex metabolic homeostasis is supported by systematic 
analyses of tissue-, time-, and stimuli-dependent NR gene expression.8  
The NRs are defined by common structural motifs as depicted in Figure 1A. A highly 
variable NH3-terminal region contains a ligand-independent activation domain called AF-
1. The central DNA-binding domain (DBD), consisting of two highly conserved zinc-
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finger motifs unique to NRs, targets the receptor to specific DNA REs. Binding specificity 
by various receptors is largely achieved by the spacing (the 3-4-5 rule) and the orientation 
of two half-sites (direct-, inverted- or everted-repeat) (Figure 2). The hinge region confers 
structural flexibility in the receptor dimers allowing a single receptor dimer to interact with 
multiple RE sequences. The C-terminal ligand-binding domain (LBD) is functionally very 
unique to NRs and responsible for: (1) receptor dimerization; (2) ligand recognition and (3) 
cofactor interaction. 
 
Figure 1. Schematic diagrams for a common domain structure of NRs which include N-terminal activation 
function 1 (AF-1), DNA binding domain (DBD) consisting of two zinc fingers (ZF), non-conserved hinge-
region (Hinge), ligand binding domain (LBD), and C-terminal AF-2 helix.8  
 
 
 
Figure 2. Schematic diagrams for NR dimerization and DNA binding sequences. From the left, homodimeric 
endocrine receptor (Palindrome RE), RXR heterodimers (Direct Repeat RE) and monomeric orphan receptor 
(Half Site RE). Arrows: the consensus NR recognition sequence AGGTCA or a variant.8 
 
2. Nuclear Receptors subtypes 
The NRs can be broadly classified into three sub-groups based on their physiologic 
ligands and potential functions (Figure 3). The first class comprises endocrine receptors 
which act as high affinity receptors for fat-soluble hormones and vitamins (Kd = nM 
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range). This class includes receptors for the steroid hormones, thyroid hormone (thyroid 
hormone receptor; TR), and vitamins A (retinoic acid receptors; RAR) and D (vitamin D 
receptor; VDR), which are all essential for homeostatic control of the endocrine system. 
Mechanistically, the steroid receptors function as homodimers and TR, VDR, and RAR 
form heterodimers with the Retinoid X Receptor (RXR).  
 
Human Nuclear Hormone Receptor Superfamily 
Endocrine Receptor Adopted orphan 
receptor 
Orphan Receptor 
Steroid Receptor 
GR           Glucocorticoids  
MR          
Mineralocorticoids  
PR            Progesterone 
AR           Androgens 
ER α,β     Estrogens 
Lipid Sensors 
PPAR α,β,γ    Fatty acids 
RXR α,β,γ      9cRA 
LXR α,β         Oxysterol  
FXR                Bile acids  
PXR                Xenobiotics  
SHP                                ? 
DAX-1                           ? 
TLX                               ? 
PNR                               ? 
GCNF                            ? 
TR2,4                            ? 
NRA4 α,β,γ                   ?    
Rev-erb α,β                   ? 
COUP α,β,γ                  ? 
 
Heterodimeric Receptors 
TR α,β        Thyroid 
hormone 
RAR α,β,γ  Retinoic acid  
VDR           Vitamin D(bile 
                   acid)       
 
Enigmatic Receptors 
CAR                Androstane  
HNF-4α,γ        Fatty acid 
SF-1/ LRH-1   
Phospholipids 
ROR α,β,γ       Cholesterol 
&      
                        Retinoic acid 
ERR α,β,γ       Estrogen??  
 
 
Figure 3. Human NR superfamily including 48 family members. Representative natural ligands are shown at 
right. Physiological importance of ligand-induced NR activation has been established for “Endocrine 
Receptors” (Purple: homodimerizing steroid receptors, and Red: RXR heterodimers); “Adopted Orphan 
Receptors” (Orange); “Enigmatic Adopted Orphans” (Blue); and “Orphan receptors” (Grey).8 
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The second receptor class is the adopted orphans, which were originally identified 
based on sequence homology to endocrine receptors. These receptors were previously 
classified as orphans as no known natural ligands were identified, but later “de-
orphanized” by subsequent identification of naturally occurring ligands. Identification of a 
vitamin A derivative, 9-cis retinoic acid, as an endogenous high-affinity ligand for RXR 
represented the first true adoption of an orphan NR and ushered in the age of “reverse 
endocrinology” in which a receptor is used to discover its natural ligand.9 This class now 
includes low affinity (Kd = μM range) receptors for dietary lipids and xenobiotics, which 
all function as heterodimers with RXR. Some RXR heterodimers can be activated by RXR 
ligands (permissive) but others cannot (non-permissive).10 Included within adopted 
orphans are ‘‘enigmatic’’ adopted orphans, for which a ligand has been identified, at least 
for one of the subtypes, but the nature of ligand-dependent regulation in physiology has not 
been established.  Receptors of this class are the most promising drug targets for metabolic 
disorders as they regulate lipid and/or glucose homeostasis by controlling uptake, 
synthesis, storage or clearance. 
The third class of NRs comprised of true orphans whose ligand (natural or synthetic) 
has not been identified. This class includes receptors which are most likely not regulated 
by ligands based on the size of the ligand binding pocket and the position of AF-2 helix in 
the apo-form in X-ray crystal structures (NR4A).11 Most likely they are regulated by 
coactivator availability, receptor expression itself, covalent modification or a combination 
of all of these. This class of orphan receptors has attracted considerable interest since they 
could lead to the discovery of new endocrine regulatory systems. 
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Since transcriptional activity of many NRs can be modulated by lipophilic ligands, and 
in turn NRs control fundamental processes important for metabolic and energy 
homeostasis, NRs provide a powerful platform for drug discovery to treat metabolic 
disease. Indeed, a number of synthetic ligands for endocrine receptors as well as adopted 
orphan receptors are currently in clinical use or under clinical trial (Table 1).8 In addition 
to the receptors that we described here, there are a number of orphan receptors about which 
little is known. As an obesity pandemic and associated illnesses such as type-2 diabetes 
and cardiovascular disease spread around the globe, particular attention has been focused 
on the role of NRs in the pathophysiology and/or treatment of metabolic diseases including 
the metabolic syndrome. Here, we review the current understanding of NR biology in the 
context of metabolic regulation and disease. 
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Table 1. NRs associated with metabolic disease, and their synthetic ligands 
Receptor (or 
coactivator) 
Associated metabolic 
disease or pathologies 
Synthetic ligand or 
modulator being used 
to ameliorate 
metabolic disease 
Other 
representative 
synthetic ligands 
GR Viceral obesity, 
hyperglycemia 
N/A Dexamethasone, 
RU38486 
MR Hypertension Aldosterone antagonist 
(Spironolactone, 
Eplerenone) 
Fludrocortisone 
 Cardiac failure   
TRβ Hypercholesterolemia N/A GC-1, KB-141 
PPARα Dyslipidemia Fibrate (Gemfibrozil, 
fenofibrate, clofibrate) 
WY14643 
 Atherosclerosis   
PPARγ Diabetes Mellitus, 
insulin-resistant 
Thiazolidinedione 
(pioglitazone, 
rosiglitazone) 
FMOC-L-Leucine 
 Atherosclerosis   
PPARδ Dyslipidemia N/A GW501516, 
KD3010 
 Atherosclerosis   
LXRα/β Dyslipidemia 
atherosclerosis 
N/A T0901317, GW3965
FXR Hypercholesterolemia Guggulsterone 
(antagonist) 
Fexaramine, 
GW4046 
 Bilary cholestasis Chenodeoxycholic acid 
(agonist) 
 
 Dyslipidemia   
PXR Bilary cholestasis, 
jaundice 
St. John’s wort 
(hyperforin), rifampin 
SR12813 
CAR Bilary cholestasis, 
jaundice 
Yin Zhi Huang (6,7-
dimethylesculetin) 
CITCO 
ERRα/γ Insulin resistance N/A XCT790, 4-
hydroxytamoxifen 
HNF4α MODY, type I 
Non-insulin dependent 
diabetes mellitus 
N/A N/A 
SHP Mild obesity N/A N/A 
RORα Atherosclerosis N/A  
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3. Estrogen Receptor 
The estrogen receptor (ER) is a member of the nuclear hormone family of intracellular 
receptors which is activated by the hormone 17β-estradiol (estrogen). ER functions as a 
DNA binding transcription factor to regulate gene expression. However the estrogen 
receptor also has additional functions independent of DNA binding.12 There are two 
different forms of ER, usually referred to as α and β, each encoded by a separate gene 
(ESR1 and ESR2 respectively). Hormone activated estrogen receptors form dimers, and 
since the two forms are co-expressed in many cell types, the receptors may form ERα (αα) 
or ERβ (ββ) homodimers or ERαβ (αβ) heterodimers.13 Estrogen receptors alpha and beta 
show significant overall sequence homology, and both are composed of seven domains 
from the N- to the C-terminus.   
Different ligands may differ in their affinity to the alpha and beta isoforms of the 
estrogen receptor. The natural ligand 17β-estradiol binds equally well to both receptors. 
Another natural ligand Estrone and synthetic ligand raloxone bind preferentially to the 
alpha receptor. The natural ligand Estriol and synthetic ligand genistein have more affinity 
for the beta receptor. The different estrogen receptor combinations may respond differently 
to various ligands which may translate into tissue selective agonistic and antagonistic 
effects. The ratio of α- to β- subtype concentration has been proposed to play a role in 
certain diseases.14 
The concept of selective estrogen receptor modulators is based on the ability to 
promote ER interactions with different proteins such as transcriptional coactivator or 
corepressors. These coactivator or corepressor regulates ERs transcriptional activity by 
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affecting the chromatin structure through the acetylation or deacetylation of histones, 
respectively. Estrogen receptor–mediated transcriptional activation is associated with the 
recruitment of coactivators, such as AIB1, GRIP1, SRC-1, CBP, p300, and pCAF, and 
subsequent histone acetylation. In contrast, antagonist-liganded ER is able to recruit 
corepressors. Furthermore the ratio of coactivator to corepressor protein varies in different 
tissues.15 As a consequence, the same ligand may be an agonist in some tissue (where 
coactivators predominate) while antagonistic in other tissues (where corepressors 
dominate). Tamoxifen, for example, is an antagonist in breast and is therefore used as a 
breast cancer treatment but an ER agonist in bone (thereby preventing osteoporosis) and an 
agonist in the endometrium (increasing the risk of uterine cancer).16 However the 
subcellular localization and roles of this receptor is still object of controversy. 
 
4. Peroxisome Proliferator-Activated Receptors (PPARs) 
The peroxisome proliferator-activated receptors (PPARs) are another group of nuclear 
receptor proteins that function as ligand-activated transcription factors regulating the 
expression of genes. PPARs play essential roles in the regulation of cellular differentiation, 
development, and metabolism (carbohydrate, lipid, and protein) of higher organisms. 
PPAR-α (NR1C1) (Nuclear Receptor Nomenclature Committee, 1999) was first described 
as a receptor that is activated by peroxisome proliferators, hence its name.17 Two 
additional related isotypes, PPAR-β/δ (NR1C2) and PPAR-γ (NR1C3) were then found 
and characterized. The PPAR-β/δ isotypes was called PPAR-β when it was first isolated 
from a Xenopus oocyte library.18 The PPAR-γ gene was cloned from vertebrates, including 
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Xenopus sp., mouse, and humans.18-20 PPAR-β protein sequences were not highly 
homologous to the Xenopus PPAR-β protein sequences, and were subsequently named 
PPAR-δ when identified in the mouse.21 PPAR-β was also designated FAAR (fatty acid 
activated receptor) in rats and NUC1 in humans. 
In humans, four different subtypes of PPAR-γ mRNA (-γ1, -γ2, -γ3, and -γ4) 
transcribed from four different promoters have been identified.22-24 Despite four distinct 
mRNA subtypes, PPAR-γ is expressed as two isoforms, γ1 and γ2 that differ at their N 
terminus. PPAR-γ2 is found at high levels in the different adipose tissues, whereas PPAR-
γ1 has a broader expression pattern that extends to settings such as the gut, brain, vascular 
cells, and specific kinds of immune and inflammatory.  
 
5. Transcriptional Regulation by PPAR-γ 
Differential promoter usage and alternate splicing of the gene generate three mRNA 
isoforms: PPAR-γ1 and PPAR-γ3 mRNA encode the same protein product; the PPAR-γ2 
isoform contains an additional 28 amino acids at its N-terminus. PPAR-γ1 exhibits 
widespread expression, albeit at low levels, whilst PPAR-γ2 is highly expressed in adipose 
tissue. Indeed, the receptor plays a critical role in fat cell differentiation, inducing the 
expression of adipocyte-specific genes, and promoting the formation of mature lipid-laden 
adipocytes.25, 26 Recent studies with mice genetically engineered to lack PPAR-γ have 
confirmed its critical role in the development of both white and brown adipocytes in vivo, 
and the clinical phenotypes of subjects with PPAR-γ gene mutations suggest a similar role 
in the regulation of human adipose tissue mass.27-29  
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In contrast to steroid hormone receptors, which act as homodimers, transcriptional 
regulation by PPARs requires heterodimerization with the retinoid X receptor (RXR; 
NR2B).30, 31 This PPAR/RXR heterodimer can form in the absence of a ligand. When 
activated by a ligand, it modulates transcription via binding to a specific DNA sequence 
element frequently called a peroxisome proliferator response element (PPRE). PPAR and 
RXR bind to the 5' and 3' half-sites of this element, respectively, and the 5'-flanking region 
mediates the selectivity of binding between different PPAR isotypes.32 The transcriptional 
control by PPAR/RXR heterodimers requires interaction with coregulator complexes— 
either a coactivator for stimulation or a corepressor for inhibition of target gene 
expression.33 Selective action of a given PPAR isotype in vivo probably results from a 
complex interplay at a given time point between expression levels of each of the three 
PPAR and RXR isotypes, affinity for a specific promoter PPRE, ligand and cofactor 
availability, and possibly binding of other transcription factor in the vicinity of the PPRE.34  
The gene transcription mechanism is similar to that of all NRs, as shown in Figure 4. 35 
In general, the C-terminal A/F domain of the receptor heterodimerizes with RXR-α and the 
PPAR/RXR-α complex binds to the PPRE sequence of the target gene promoters.30, 36, 37 
The PPRE motif contains a characteristic 13-nucleotide sequence, AGGTCA N AGGTCA 
(N – any nucleotide) that is composed of two hexanucleotides separated by one nucleotide 
(this type of sequences is called DR-1). The direct repeat 1 (DR-1) sites are specifically 
and almost exclusively recognized by the PPAR-γ/RXR-α heterodimer. Each component of 
the heterodimer complex binds to one hexamer of the DR-1 motif. The unactivated PPAR-
γ is associated with a corepressor that silences its transcriptional activity by the recruitment 
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of histone deacetylases, such as the NR corepressor, the silencing mediator of retinoid and 
thyroid receptors (repression step). The binding of exo- or endogenous ligand to the 
receptor stimulates the release of the corepressor and the recruitment of a coactivator, 
which contains a protein with histone acetyl transferase (HAT) activity such as CREB 
(cAMP response element binding protein) binding protein (CBP/p300) or SRC-1 
(derepression step). The action of acetyltransferases leads to chromatin decondensation. 
Following, the HAT complex dissociates and either transcription factors or the RNA 
polymerase II initiation complex are recruited to the accessible promoter, resulting in 
transcription activation of the target gene (transcription activation step). Interactions of 
PPAR-γ with a coactivator or corepressor thus regulate its transcriptional activity by 
affecting the chromatin structure through the acetylation or deacetylation of histones, 
respectively. 
It should be mentioned that both coactivators and corepressors are highly versatile and 
are not selective for particular PPAR subtypes. It has been observed, for example, that all 
three members of the PPAR family are subjected to transcriptional coactivation by the 
PPAR-γ coactivator-1α (PGC-1α), which is highly expressed in tissues with high 
mitochondrial metabolism, such as brown adipose tissue, heart, and skeletal muscle.33, 38-40  
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Figure 4. Transcriptional activity of PPARs. (A) The promoter region with a PPRE, the TATA box, and the 
transcription start site is located in a repressive chromatin structure. The binding of ligand to the 
PPAR/RXR/corepressor complex causes the release of the corepressor from the ligand-activated PPAR/RXR 
complex. (B) The activated PPAR/RXR complex binds to the PPRE, inducing structural change in 
chromatin, with histone H1 released. The PPRE-bound PPAR/RXR targets a coactivator-acetyltransferase 
complex to the promoter. (C) The coactivator-acetyltransferase complex acetylates the histone tails (Ac), 
thereby generating a transcriptionally active structure. (D) Additional transcription factors (TF) and the RNA 
Pol II initiation complex are recruited to the accessible promoter and transcription is initiated.35, 41  
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6. Functional and Medicinal Roles of PPARs  
As noted above, there are three different PPAR isotypes namely PPAR-α, -δ, and –γ, 
which have been identified in vertebrates and have distinct pattern of distribution. PPARs 
are important targets for the drugs used in the treatment of atherosclerosis, dyslipidaemia, 
obesity, diabetes, and other disease caused by abnormal regulation of glucose and lipid 
metabolism. 
PPAR-α is distributed in tissues with high catabolic rates of fatty acids and high 
peroxisomal activity, and the major role of PPAR-α is the regulation of energy 
homeostasis.42 In liver, PPAR-α activates fatty acid catabolism, stimulates gluconeogenesis 
and ketone body synthesis, and is involved in the control of lipoprotein assembly.43 PPAR-
α also stimulates heme synthesis, cholesterol catabolism, attenuates inflammatory 
responses, and participates in the control of amino acid metabolism and urea synthesis. 
Increased fatty acid oxidation by activated PPAR-α lowers circulating triglyceride levels, 
liver and muscle steatosis, and reduces adiposity, which improves insulin sensitivity.44 The 
fibrate drugs such as gemfibrozil, clofibrate, and fenofibrate that are widely used to treat 
hypertriglyceridemia are activators of PPAR-α. In addition, PPAR-α agonists have 
demonstrated significant anti-inflammatory activities that seem to play a role in their 
protective actions within the cardiovascular system.45 
PPAR-δ is necessary for placental and gut development and is also involved in the 
control of energy homeostasis by stimulating genes involved in fatty acid catabolism and 
adaptive thermogenesis.46, 47 In addition, PPAR-δ has an important role in the control of 
cell proliferation, differentiation, and survival and is involved in tissue repair.48 In animal 
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models, PPAR-δ agonists retard weight increase under high-fat diet conditions and 
therefore maintain insulin sensitivity probably by stimulating skeletal muscle fatty acid 
metabolism and thermogenesis.40 
PPAR-γ is a pivotal actor in adipose tissue differentiation and in maintaining adipocyte 
specific functions, such as lipid storage in the white adipose tissue and energy dissipation 
in the brown adipose tissue.49, 50 In addition, PPAR-γ is involved in glucose metabolism 
through an improvement of insulin sensitivity and thus represents a molecular link between 
lipid and carbohydrate metabolism. Like PPAR-α, -γ activation seems to limit 
inflammation, adding to the interest in its possible role in limiting atherosclerosis and/or 
diabetes.51, 52 Among the synthetic compounds that selectively activate PPAR-γ, the 
thiazolidinediones (TZDs) are insulin sensitizers used to treat the hyperglycemia of type 2 
diabetes.53, 54 The clinical use of these agonists and the discovery of both rare and severely 
deleterious dominant-negative mutations that lead to a stereotyped syndrome of partial 
lipodystrophy and severe insulin resistance, as well as more common sequence variants 
with a much smaller impact on receptor function, have increased our understanding of the 
functions of PPAR-γ in humans.55 Finally, growing evidence implicates PPAR-γ, as well 
as the two other isotypes, in tumor development in different tissues, although whether 
PPAR activation promotes or limits this process remains under debate and may depend on 
specific conditions.56, 57 
 
7. Structure of PPAR 
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All three PPAR isotypes have a protein domain organization similar to most members 
of the superfamily (Figure 1A). This includes the NH3-terminal region, the central DNA-
binding domain (DBD), the hinge region, and the C-terminal ligand-binding domain 
(LBD). The best-characterized domains are the DBD and LBD. Although the latter is 
generally less well conserved than the former, X-ray crystal structure analyses have 
revealed a three dimensional fold of the PPAR LBD that is similar to other nuclear 
receptors. 
The N-terminal domain A/B has been relatively well conserved through evolution. The 
chief fragment of this domain is α-helix fragment possessing a ligand-independent 
activating function (AF-1). It has been shown that the hPPAR-γ2 isoform exhibits tenfold 
higher activity than hPPAR-γ1 in the presence of insulin in ligand-independent 
transcriptional activation.58 This data may imply different functions of the two isoforms 
that differ only in their N-termini. So far, the role of the additional 28 amino-acid residues 
at the N-terminus of the hPPAR-γ2 protein has not been explained. However, there are 
some hypotheses about this fragment concerning its effect on an increase in receptor 
activity.59 Furthermore, in the A/B domain is Ser112, which is subject to phosphorylation. 
Since intramolecular communication between the A/B and the LBD domains is required 
for ligand binding, the phosphorylation at Ser112 by mitogen-activated protein kinase 
(MAPK) disrupts interdomain communication, resulting in a reduction in ligand-binding 
affinity.60 Moreover, the MAPK-dependent phosphorylation of this residue in the hPPAR-
γ2 protein inhibits its ability to promote specific gene expression and the process of 
adipogenesis.61 
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 The C domain is the most conserved of all the functional domains. It contains two zinc 
finger-like motifs that are responsible for binding of the receptor to the DNA promoter of 
target genes. Each of the zinc fingers is encoded by a separate exon (2 and 3). Besides the 
zinc fingers there are amino-acid motives determining the recognition of an appropriate 
DNA sequence which binds the receptor. Additionally, a large part of the domain takes 
part in dimerization with another nuclear receptor, RXR.  
The less conserved domain D is a flexible hinge between the C and E/F domains.35 
This site is also a docking domain for cofactors. In addition, it contains the nuclear 
localization signal, a sequence recognized by transporting proteins, which determines 
relocation of the synthesized protein from the cytoplasm to the cell nucleus. Moreover, 
some of the amino acids are involved in the activities of both nearby domains, leading to 
the dimerization and recognition of the target DNA sequence.  
 
8. Ligand Binding Domain 
The largest structural domain of PPAR is the LBD (E/F domain) located at the C-
terminus, and responsible for the binding of a specific ligand and activation of PPAR 
binding to PPREs in the target gene promoter. The PPAR LBD consists of 12 α-helices 
that form the characteristic three-layer anti-parallel α-helical sandwich with a small four-
stranded sheet. This structure delineates a large Y-shape hydrophobic pocket, the ligand-
binding cavity, which is larger in PPARs than in other receptors.62, 63 This feature may 
contribute to the ability of PPARs to bind a wide range of synthetic and natural lipophilic 
compounds with an acidic head group. Comparison of the ligand-binding pocket of the 
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three PPAR isotypes has revealed the following interesting characteristics.64 The PPAR-δ 
ligand-binding pocket is significantly smaller than the corresponding PPAR-α and PPAR-γ 
pockets, which are similar to each other in shape and size. This difference might explain 
why fewer PPAR-δ ligands have been reported compared with PPAR-α and PPAR-γ and 
may indicate that the size of the pocket contributes to the ligand-binding specificity of this 
isotype. The PPAR-α pocket is more lipophilic than the two others, which suggests a 
possible explanation for why certain potent PPAR-γ ligands do not bind PPAR-α and why 
PPAR-α can bind the more lipophilic-saturated fatty acids. Finally, it is important to note 
that single amino acid differences in the pockets can be major determinants of ligand 
isotype selectivity. 
The LBD contains a fragment called ligand- dependent activation function 2 (AF-2), 
engaged in the recruitment of PPAR cofactors to assist the gene transcription processes.62, 
65 Ligand-dependent activation of PPAR stabilizes the LBD in a relatively compact and 
rigid structure in which helix 12 is in a confirmation that promotes binding of coactivator 
proteins and thus has a critical function in the stimulation of target genes.62, 66 Examples of 
coactivators are CBP/p300 and steroid receptor coactivators (SRC-1), PGC-1, RIP140, 
ARA70. Usually nucleosome remodeling, for example by histone deacetylation and 
repositioning, is necessary to allow formation of the transcription preinitiation complex. 
Alternatively, corepressors inhibit the activity of the receptors in the absence of a ligand or 
upon antagonist treatment. Examples of corepressors are SMRT and NCOR. Often, the 
repressive effects depend on the recruitment of histone deacetylases, but sometimes direct 
contacts with the basal transcription machinery are also possible.67, 68  
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A “mouse trap” model of receptor activation has been proposed. According to this 
model, helix 12, containing the conserved AF-2 core, closes the ligand binding site in 
response to a bound ligand, resulting in a transcriptionally active form of the receptor.69 
The recently solved X-ray structure of the PPAR-γ/RXRα LBD heterodimer in complex 
with a synthetic ligand, GW409544 and two LXXLL (L, leucine; X, any amino acid) 
peptides from SRC-1 revealed that the acidic head group of GW409544 forms hydrogen 
bonds with either His-323 (helix 5) or Tyr-473 (the AF2 helix) within PPAR-γ. In addition, 
comparison of the structures of GW409544 bound to PPAR-α and PPAR-γ, along with 
mutational analysis of their LBDs, resulted in the identification of the single amino acids 
which determine ligand selectivity. These are Tyr-314 in PPAR-α and His-323 in PPAR-γ, 
which constitute part of the network of hydrogen-binding residues involved in the 
activation of PPAR through its acidic ligands.64 It is noteworthy that the identification of a 
major determinant of selectivity between PPAR-α and PPAR-γ has provided the 
opportunity to design new diabetes drugs. Currently however, synthetic ligands like TZDs 
and tyrosine agonists remain the most potent known activators of PPAR-γ. 70 
The crystal structure of the apo-PPAR-γ LBD reveals a bundle of 13 α-helices and a 
small four-stranded β-sheet (Figure 5). The PPAR-γ LBD is very similar to the overall fold 
of other nuclear-receptor structures from helix 3 to the C terminus. However, PPAR-γ is 
unique in its overall tertiary structure and contains an extra helix, designated H29, between 
the first beta-strand and helix H3. The tertiary placement of helix H2 is different in PPAR-
γ compared with other nuclear-receptor LBD tertiary structures, and provides easier access 
for ligands. Helices H4, H5 and H8 are tightly packed between helices H1, H3, H7 and 
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H10 at the top half of the LBD. This structural arrangement seems to be important in 
forming the ligand-binding site: helices H3, H7 and H10 are anchored to allow them to jut 
downwards and form the scaffolding for the large cavity of the ligand-binding site in 
PPAR-γ. The binding cavity of the apo-PPAR-γ LBD site is T-shaped and extends from 
the C-terminal helix to the β-sheet lying between helices H3 and H6. This domain is 
mainly hydrophobic and is buried within the bottom half of the LBD. One region of the 
domain is 20Å in length, lies between helix H3 and the β-sheet, and is parallel to helix H3. 
Another cavity, which extends from the β-sheet to the C-terminal AF-2 helix and is 16 Å in 
length, is orthogonal to the T-shaped cavity, behind helix H3.62  
The crystal structure of PPAR-γ LBD in complex with the TZD, Rosiglitazone and co-
activator, SRC-1 has been elucidated, and shows Rosiglitazone to occupy roughly 40% of 
the ligand-binding site in the ternary complex (Figure 6). In general the ligand is in a U-
shaped conformation, wrapping around helix H3 with its central benzene ring directly 
behind H3 and the thiazolidinedione head group and pyridine ring wrapping around helix 
H3. The thiazolidinedione head group makes several specific interactions with amino acids 
in helices H3, H4, H10 and the AF-2 helix (Figure 6). The carbonyl groups of the TZD 
form hydrogen bonds with two histidine residues, H323 and H449. Y473 in the AF-2 helix 
forms a secondary hydrogen-bond interaction with H323. The partly negatively charged 
nitrogen of the TZD head group is within hydrogen-bonding distance of the Y473 side 
chain hydroxyl group. A buried lysine residue, K367, forms another secondary hydrogen-
bond interaction with the ligand mediated by residue H449. All of these primary and 
secondary hydrogen-bond interactions result in a fixed conformation of the 
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thiazolidinedione head group and of the participating amino acids. Next to the head group, 
the sulfur atom of the thiazolidinedione ring is positioned in a hydrophobic region of the 
PPAR-γ ligand-binding pocket formed by F363, Q286, F282 and L469. The central 
benzene ring of the ligand occupies a very narrow pocket between C285 and M364. The 
bridging oxygen atom between the benzene ring and the pyridine ring provides vital 
geometry for the pyridine ring, which occupies the pocket between helix H3 and the β-
sheet.  
 
9. Rationale and Hypothesis 
PPAR-γ plays a vital role in adipose tissue differentiation.71 In addition, PPAR-γ is 
involved in glucose metabolism through an improvement of insulin sensitivity and thus 
represents a molecular link between lipid and carbohydrate metabolism.51, 72 Like PPAR-α, 
PPAR-γ activation seems to limit inflammation, adding to the interest in its possible role in 
limiting atherosclerosis and/or diabetes.52 Among the synthetic compounds that selectively 
activate PPAR-γ, the thiazolidinediones (TZDs) are insulin sensitizers used to treat the 
hyperglycemia of type 2 diabetes.53, 54, 73 TZDs have been shown to selectively stimulate 
lipogenic activities in fat cells resulting in greater insulin suppression of lipolysis.74 Two of 
these TZD, Rosiglitazone and Pioglitazone are clinically approved for the treatment of type 
2 diabetes mellitus and offer a new approach in the pharmacologic management of this 
disease. Unlike other oral antidiabetic agents, TZDs are unique because they improve 
insulin sensitivity by increasing insulin-mediated glucose uptake in skeletal muscle, 
suppressing hepatic glucose output and improving the secretory response of insulin in  
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Figure 5. Crystal structure of the apo-PPAR-γ.62 
 
Figure 6. Crystal structure of PPAR-γ LBD in complex with Rosiglitazone.62 
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pancreatic β-cells. The findings that TZDs could form a number of reactive intermediates, 
including quinones and quinone methides, led investigators to hypothesize that TZDs 
hepatotoxicity was mediated by these intermediates through either a classic Glutathione 
(GSH)depletion/covalent binding mechanism or via oxidative stress caused by redox 
cycling of the quinone. This would potentially explain the zone 3 centrilobular necrosis 
produced by TZDs in the liver as P450 activities are higher and GSH levels are lower in 
this zone than in others. Quinones are also well-established cytotoxic agents and can 
produce toxicity by redox cycling with molecular oxygen to produce superoxide anion 
radical and subsequent oxidative stress.75 
The TZDs are indicated in the United States for monotherapy and as combination 
therapy with sulfonylureas, metformin and insulin for treatment of type 2 diabetes 
mellitus.76, 77As monotherapies, both Rosiglitazone and Pioglitazone significantly improve 
insulin sensitivity and glycemic control in type 2 diabetes mellitus patients by decreasing 
plasma glucose and plasma insulin levels, thus reducing HbA1c levels from 0.5% to 
1.9%.78, 79 In combination therapy with other oral diabetes medications, both Rosiglitazone 
and Pioglitazone demonstrate additive effects on glycemic control compared with 
monotherapy.76 
After studying the crystal structure of Rosiglitazone in the binding pocket of PPAR-γ 
LBD with the co-activator SRC-1,62 we decided to design novel PPAR-γ agonistic ligands 
based on the mode of Rosiglitazone interactions with PPAR-γ LBD.  
The objective is to take advantage of the PPAR-γ LBD binding site characteristics and 
the mode of binding of known PPAR-γ agonists to rationally design novel agonists of 
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PPAR-γ. The goal is to generate new and potent PPAR-γ agonists that could be used to 
treat diabetes. Our working hypothesis is that these compounds will bind to PPAR-γ LBD 
and exhibit agonistic effects. To achieve our goal the study was divided into five specific 
aims: 
 
Aim 1. Expression and purification of PPAR-γ LBD. 
Aim 2. Molecular modeling to design PPAR-γ receptor modulators. 
Aim 3. Synthesis of potential PPAR-γ receptor modulators. 
Aim 4. Functional studies to determine the binding affinity of PPAR-γ receptor 
modulators. 
Aim 5. Structural studies of PPAR-γ LBD in complex with PPAR-γ receptor modulators. 
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{CHAPTER II Experimental Methods} 
 
 
1.   Expression and Purification of PPAR-γ LBD. 
The plasmid containing the LBD fragment of the human PPAR-γ (residues 195-477) 
and a pGEX-4T1 vector with GST gene (GE Healthcare) were digested with restriction 
enzymes BamH1 and Xho1, and then run on an agarose gel. The LBD fragment and the 
pGEX-4T1 vector were extracted from the gel using a Qiagen (Valencia, California) DNA 
extraction kit and then ligated with T4 DNA ligase (Novagen). The ligated plasmid was 
transformed into Rosetta (DE3) cells (Novagen), which were grown at 37°C in LB medium 
containing 50μg/ml kanamycin and 34μg/ml chloramphenicol, and after reaching an 
OD600nm of 1.0, it was induced with 1.0 mM isopropyl-β-D thiogalactopyranoside (IPTG). 
Incubation was carried out in a mechanical shaker at 37°C for 18 hours (overnight). Cells 
were harvested with centrifugation and broken with Avestin EmulsiFlex-C3 homogenizer. 
The solution was saturated with ammonium sulfate to 20% and the precipitate discarded. 
Second ammonium sulfate treatment (45% saturation) yielded a precipitate with 98% of 
the activity of the lysate. Cells were collected by rapid centrifugation and resuspended in 1 
X PBS (137 mM NaCl, 2.7 mM KCl, 4.3 mM Na2HPO4, 1.47 mM KH2PO4), pH 7.4, and 1 
mM dithiothreitol (DTT) containing 1 mM phenylmethylsulfonyl fluoride and dialyzed 
overnight against the same buffer. The GST-PPAR fusion protein was purified from the 
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cell pellet using glutathione-sepharose beads, following the procedure recommended by 
the manufacturer (Amersham Pharmacia Biotech). The dialyzed protein was then 
centrifuged at 5,000 rpm, to remove some of the turbidity so that it does not clog the 
column.  The protein was loaded on to a previously equilibrated GST-column with 1 X 
PBS buffer, and then washed with 200 ml of 1 X PBS buffer to remove extra non-bound 
protein. For removal of the GST moiety, we digested the fusion protein with thrombin 
(Pharmacia) on the column. The cleaved PPAR-γ LBD was eluted with elution buffer (50 
mM Tris-HCl, 10 mM reduced glutathione), pH 8.0. The protein yield was 5mg/L 
determined using Bradford assay. Due to poor expression, as well as time consuming and 
labor intensive purification procedure, an alternate method was developed (see below) for 
obtaining pure protein with better yield. 
The plasmid containing the LBD fragment of the human PPAR-γ (residues 204-477) 
amplified from a cDNA library from human fetal brain tissue (Invitrogen), was obtained 
from our Brazilian collaborators, Polikarpov and colleagues, and transferred to competent 
Rossetta cells (Strat-agene). The transformed cells were grown in Luria-Bertani medium 
containing 50μg/ml kanamycin and 34μg/ml chloramphenicol at 37˚C. At OD600nm of 0.5, 
the expression was induced by addition of 0.1 mM IPTG for 18 hours (overnight) at 25˚C. 
Cells were harvested with centrifugation and broken with Avestin EmulsiFlex-C3 
homogenizer. Cell lysis was performed using lysozyme treatment followed by 
homogenization. After collecting the soluble fraction, the protein product was isolated in a 
single purification step by immobilized metal affinity chromatography using the Ni-
nitrilotriacetic acid (NiNTA) coloumn (Invitrogen), previously equilibrated with the 
   
 27
running buffer 50 mM NaCl, 25 mM Tris-HCl, pH 8.0. The PPAR-γ LBD bearing a His-
tag fused to its N terminus was eluted stepwise using running buffer to which up to 200 
mM imidazole had been added. After purification, 5 mM DTT was added to the buffer. 
The purity of the protein was determined to be greater than 95% using SDS gel 
electrophoresis.  
2. Molecular Modeling to Design PPAR-γ Receptor Modulators. 
A. Design:  
Our purpose was to use the binding mode of Rosiglitazone in PPAR-γ LBD to design 
potent agonists of this nuclear receptor. The molecular modeling program Sybyl, and the 
crystallographic modeling programs TOM80 and COOT81 were used for the design studies. 
The known crystal structure of PPAR-γ LBD in complex with Rosiglitazone (PDB code 
2PRG) was used as the docking model. 
Figures 6 and 7 show the binding of Rosiglitazone to PPAR-γ LBD (PDB code 2PRG). 
The carbonyl groups of the TZDs form hydrogen-bond interactions with the side-chains 
NE2 atoms of His323 and His449. The partly negatively charged nitrogen of the 
thiazolidinedione moiety is within hydrogen-bonding distance of the Tyr473 side chain 
hydroxyl group. The central benzene ring of the ligand occupies a very narrow pocket 
between Cys285 and Met364. Binding of ligand is believed to activate a nuclear receptor 
heterodimer, PPAR-γ/ RXR-α through covalent binding to Cys285 in PPAR-γ LBD.82 The 
bridging oxygen atom between the benzene ring and the pyridine ring provides vital 
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geometry for the pyridine ring, which occupies the pocket between helix H3 and the β-
sheet. 
Based on the binding mode of Rosiglitazone, we reasoned that increased affinity and 
agonistic activity of ligands to PPAR-γ LBD can be obtained by exploiting some potential 
binding interactions as noted below.  
1.  The residue, Cys285 could be utilized to make potential hydrogen-bond 
interaction with the ligand. 
2. There is a hydrophobic cavity formed by Ile281, Met348, Ile341 and 
Arg288 near the pyridine ring of Rosiglitazone, which can be utilized to 
make hydrophobic contact with the ligand.   
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Figure 7. Rosiglitazone in crystal structure with PPAR-γ LBD. 
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Figure 8. A. Structural components of PPAR-γ LBD agonists. B. Structural design of type-I compounds. C. 
Structural design of type-II compounds. 
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Based on these assumptions, we identified two important parts of the Rosiglitazone 
structure – the thiazolidinedione core structure and the hydrophobic agonistic side-chain as 
shown in Figure 8A. Using these two identified pharmacophores, two classes of novel 
compounds can be designed. We will call these type-I and type-II compounds. For the 
type-I compounds, the ether bridge between the core structure and the hydrophobic side 
chain is modified as an amide without extending the hydrophobic chain length. An 
example of type-I compound (compound A) is shown in Figure 8B.  This class of 
compounds is hypothesized to bind similarly as Rosiglitazone but with additional 
hydrogen-bond interaction between the amide oxygen of the ligand and Cys285 of PPAR-γ 
LBD. 
For type-II compounds, in addition to replacing the ether linkage with an amide 
moiety, the hydrophobic part is also extended by incorporating additional ring (isoxazole 
or furan) to the phenyl substituent. An example of type-II compound (compound B) is 
shown in Figure 8C. This compound is proposed to bind to increase both hydrogen-bond 
and hydrophobic interactions with the protein. 
B. Docking: 
 Using SYBYL 7.3, representative molecules of these two classes (compound A from 
type-I and B from type-II) were built and energy minimized. The crystallographic structure 
of PPAR-γ LBD in complex with Rosiglitazone was obtained from the Protein Data Bank 
(PDB code 2PRG) and used as the target molecule for docking the minimized compounds 
A and B. Prior to docking the molecules into the target, hydrogen atoms which are not part 
of the 2PRG structure were added to the protein using tools within SYBYL 7.3. The added 
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hydrogen atoms were energy minimized to reduce steric clashes with the protein residues 
to a gradient of 0.005 using Gasteiger Hϋckel charges, a dielectric constant of 1.0, and a 
gradient of 0.005Kcal/mol Å with 10,000 iterations. 
This ensures the ideal position and conformation for the added hydrogen atoms. The 
coordinates of all non-hydrogen atoms were not altered during the minimization and were 
kept fixed.83 The individual software programs used for the studies are all incorporated in 
the molecular modeling and graphic program SYBYL 7.3 (Tripos Inc) software suite.  
The molecules were then manually docked into the known crystal structure of PPAR-γ 
LBD using TOM and/or COOT, and then energy minimized with a subset of the active site 
residues using SYBYL. A hot radius of protein-ligand subset of 6 Å, and surrounding 
radius of 12 Å were used for the computation. Other conditions specified for the 
minimization process include Gasteiger Hückel charges, dielectric constant of 1.0, a 
gradient of 0.005 and 10,000 iterations, whereas the coordinates of all other atoms outside 
the subset were kept fixed. As a control, we also energy minimized the crystallographically 
bound Rosiglitazone.  
Subsequently, the docked molecules were subjected to HINT (eduSoft, LC) analysis, to 
analyze the interactions between the compounds and the protein. HINT uses a scoring 
function that employs empirically derived parameter log Po/w (partition coefficient for 1-
octanol/water) - utilizing fragment rules of Hansch and Leo. 84, 85 The program calculates a 
score for each interaction between various atoms of the protein and ligand, and the 
cumulative score is termed as HINT score. A positive HINT score value indicates 
hydropathically favorable contacts (hydrogen bonds, acid/base, and 
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hydrophobic/hydrophobic), while negative value indicates unfavorable contacts (acid /acid, 
base/base, and hydrophobic/polar). The factor log Po/w of a ligand or biological molecule is 
the sum of all the hydrophobic atomic constants for that molecule, and directly correlated 
with free energy. HINT score therefore reveals information not only about enthalpy but 
also entropy of the bimolecular complex.83, 86, 87 
 
3. Synthesis of Potential PPAR-γ Receptor Modulators.  
1H-NMR (Proton Nuclear Magnetic Resonance) spectra were obtained on a Varian 
Gemini 300 MHz spectrometer and tetramethylsilane was used as an internal standard. 
Routine thin-layer chromatography (TLC) was performed on silica gel GHIF plates (250 μ, 
2.5 x 10 cm; Analtech Inc., Newark, DE). Elemental analysis was performed by Atlantic 
Microlab, Inc. 
 
A. Chemical Synthesis: 
Based on the above design studies, we devised three synthetic schemes, Scheme 1 - 3 
to synthesize type-I and -II compounds. In scheme 1, we synthesized 5-(4-Amino-
benzylidene)-thiazolidine-2,4-dione or (4), which is the common starting material for type-
I and -II compounds. Scheme 2 involves synthesis of type-I compounds, including A, D, 
G, H and I. Scheme 3 involves synthesis of a type-II compounds, including B, C, F, J and 
K. We note that even though attempts were made to synthesize compounds G, H and I 
from type-I and J and K from type-II (shown in schemes 2 and 3 in results and discussion 
part), we failed to obtain the end products. The proceeding synthetic procedures are those 
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for the compounds that we were able to synthesize, which are similar to the procedures 
used for synthesizing the failed compounds. 
 
a. Intermediates: 
5-(4-Amino-benzylidene)-thiazolidine-2,4-dione , 4:  
In scheme 1, 5-(4-Amino-benzylidene)-thiazolidine-2,4-dione or 4 was synthesized 
using a two step reaction procedure. 
 In step 1, a mixture of 4-nitrobenzaldehyde, 1 (5.0g, 33 mmol), 2,4-thiazolidinedione, 
2 (3.9 g, 33 mmol), piperidine (0.5 mL) and acetic acid (0.5 mL) in toluene (100 mL) was 
heated to reflux with Dean Stark apparatus for 16 hours. The mixture was cooled in ice, the 
precipitate filtered, and washed with cold toluene. The product was re-crystallized from 
methanol to yield 5-(4-nitro-benzylidene)-thiazolidine-2,4-dione, 3, to yield 5.07 g (61%); 
1H NMR (CD3COCD3) δ 7.77-7.80 (m, 3H), 8.26-8.29 (m, 2H), 12.4 (br, H).  
In step 2, to a stirring solution of 3 (3.0 g, 12 mmol) in ethanol (100 mL) was added tin 
(II) chloride (13.6g, 60 mmol) and the mixture heated to reflux for 2 hours. The reaction 
mixture was cooled and neutralized with sodium bicarbonate and the product extracted 
with ethyl acetate (3 x 200 mL). The organic layer was dried (MgSO4), filtered and 
evaporated at reduced pressure to yield of 1.4 g (53%); 1H NMR (CD3COCD3) δ 6.1 (br, 
2H), 6.8 (d, 2H, J = 8.7 Hz), 7.4 (d, 2H, J = 8.4 Hz), 12.3 (br, H). 
 
b. Synthesis of Type-I Compounds: 
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In scheme 2, compounds A and D were synthesized as follows: 
N-[4-(2,4-Dioxo-thiazolidin-5-ylidenemethyl)-phenyl]-3-phenyl-propionamide, A:  
To a mixture of 4 (500 mg, 2.3 mmol), and triethylamine (0.92 mg, 9.2 mmol) in 
dichloromethane (30 mL) at 0° C and under nitrogen was added hydrocinnamoyl chloride, 
5 (383 mg, 2.3 mmol,) in dichloromethane (30 mL) dropwise. After stirring at the same 
temperature for ten minutes, the mixture was further stirred at room temperature for 2 hr. 
The mixture was washed with dilute hydrochloric acid (2 x 30 mL), and aqueous sodium 
bicarbonate (2 x 30) followed by brine (30 mL). The organic layer was dried (MgSO4), 
filtered and evaporated at reduced pressure to yield 500 mg (61%). 1H NMR (CD3COCD3) 
δ 2.7 (t, 2H, J = 7.8 Hz), 3.0 (t, 2H, J = 7.5 Hz), 7.2 (t, H, J = 4.8 Hz), 7.3 (d, 4H, J = 6.9 
Hz), 7.7 (s, H), 7.8 (d, 2H, J = 6.9 Hz). Anal. calc. for C19H16N2O3S : C, 64.76; H, 4.58; N, 
7.95; Found : C, 64.50; H, 4.65; N,7.88. 
 
N-[4-(2,4-Dioxo-thiazolidin-5-ylidenemethyl)-phenyl]-2-(pyridin-3-yloxy)-acetamide, D:  
To a mixture of 4 (500 mg, 2.3 mmol), 3-pyridyloxyacetic acid or 6 (348 mg, 2.3 
mmol), under nitrogen at room temperature was added 1-hydroxybenzotriazole hydrate 
(HOBt) (337.5 mg, 2.53 mmol) and N-(3-dimethylaminopropyl)-N-ethylcarbodiimide 
(DEC) (523 g, 2.76 mmol), in N,N-dimethylformide (DMF) and the mixture stirred 
overnight. The reaction mixture was diluted with ethyl acetate (100 mL), washed with 
dilute hydrochloric acid (3 x 40 mL), aqueous sodium bicarbonate (3 x 40 mL) and brine 
(40 mL). The organic layer was dried (MgSO4), filtered and evaporated at reduced pressure 
to yield 450 mg (55%). 1H NMR δ 4.8 (s, 2H), 7.4 (m, 2H), 7.6 (d, 2H, J = 9.0 Hz), 7.7 (s, 
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H), 7.8 (d, 2H, J = 9.0 Hz), 8.2 (d, H, J = 4.8 Hz), 8.4 (d, H, J = 2.4 Hz), 10.4 (s, H), 12.5 
(br, H). Anal. calc. for C17H13N3O4S : C, 57.46; H, 3.69; N, 11.82; Found : C, 57.20; H, 
3.67; N, 11.69. 
 
c. Synthesis of Type-II Compounds: 
 
5-(3-Trifluoromethyl-phenyl)-furan-2-carboxylic acid [4-(2,4-dioxo-thiazolidin-5-
ylidenemethyl)-phenyl]-amide, B:  
Compound B was synthesized in the same manner as D with a mixture of 4 (1.0 g, 4.6 
mmol), 5-(3-Trifluoromethyl-phenyl)-furan-2-carboxylic acid or 7 (1.2 g, 4.6 mmol), 
HOBt (675 mg, 5.06 mmol) and DEC ( 1.0 g, 5.5 mmol), to yield 1.11 g (53%). 1H NMR δ 
6.9 (d, H), 7.4 (d, H), 7.8 (m, 9H), 9.8 (br, H). Anal. calc. for C22H13F3N2O4S : C, 57.64; 
H, 2.86; N,6.11; Found : C, 57.64; H, 2.83; N, 5.99. 
 
3-p-Tolyl-isoxazole-5-carboxylic acid [4-(2,4-dioxo-thiazolidin-5-ylidenemethyl)-phenyl]-
amide, C: 
Compound C was prepared by using same sequence as D with a mixture of 4 (1.0 g, 
4.6 mmol), 3-p-Tolyl-isoxazole-5-carboxylic acid, 8 (924 mg, 4.6 mmol), HOBt (675 mg, 
5.06 mmol) and DEC ( 1.0 g, 5.5 mmol,) to yield 1.024 g (55%). 1H NMR δ 2.4 (s, 3H), 
7.4 (d, 2H, J = 7.5 Hz), 7.4 (s, H), 7.6 (d, 2H, J = 7.8 Hz), 7.7 (s, H), 7.8 (d, 2H, J = 7.9 
Hz), 7.9 (d, 2H, J = 7.9Hz). Anal. calc. for  C21H15N3O4S : C, 62.21; H, 3.73; N, 10.36; 
Found : C, 62.42; H, 3.66; N, 10.19. 
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5-p-Tolyl-furan-2-carboxylic acid [4-(2, 4-dioxo-thiazolidin-5-ylidenemethyl)-phenyl]-
amide, F:  
Compound F was prepared by using same sequence as B with a mixture of 4 (1.0 g, 4.6 
mmol), 5-[4-Methoxyphenyl]-2-furoic acid, 9 (990 mg, 4.6 mmol), HOBt (675 mg, 5.06 
mmol) and DEC ( 1.0 g, 5.5 mmol,) to yield  1.06 g (57%). 1H NMR δ 2.4 (s, 3H), 7.1 (d, 
H, J = 3.3 Hz), 7.3 (d, 2H, J = 8.4 Hz), 7.5 (d, H, J = 3.6 Hz), 7.6 (d, 2H, J = 9.0 Hz), 7.7 
(s, H), 7.9 (d, 2H, 8.4 Hz), 8.0 (d, 2H, J = 9.0 Hz), 10.4 (s, H). Anal. calc. for 
C22H16N2O4S·0.25 H2O : C, 65.33; H, 3.99; N, 6.93; Found : C, 64.61; H, 4.07; N, 6.85. 
 
4. Functional Studies to Determine the Binding Affinity of PPAR-γ Receptor 
Modulators. 
To determine, whether the synthesized compounds are capable of binding to PPAR-γ 
LBD and their binding affinity, we performed functional studies by using a fluorescence-
based competitive binding experiment.  
 
A. Assay Mechanism: 
A fluorescence-based competitive binding assay is used to determine relative affinity 
of the test compounds for the PPAR-γ LBD as shown in Figure 9. This is a technique 
specially applied to study molecular interactions. In this assay, PPAR-γ LBD is added to 
Fluormone™ PPAR-γ Green to form a PPAR-γ LBD/Fluormone™ PPAR-γ Green 
complex.  
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Figure 9. Fluorescence based affinity binding assay. NR: nuclear receptor and F is fluorescent ligand. 
 
The binding of PPAR-γ LBD to the Fluormone ligand results in high polarization 
value. This complex is then added to individual test compounds in microwell plates. 
Competitors or test compounds displace the Fluormone ligand from the PPAR-γ-
LBD/Fluormone complex, causing the Fluormone ligand to tumble rapidly during its 
fluorescent lifetime, resulting in a low polarization value. Non-competitors will not 
displace the Fluormone ligand from the complex, so the polarization value remains high. 
The shift in polarization value in the presence of test compounds is used to determine the 
relative affinity of test compounds for PPAR-γ LBD.  
B. Assay Procedure:  
The PPAR-γ LBD receptor binding assay kits (Panvera, Madison, WI) were used to 
determine the ability of the test molecules to displace the fluormone, PPAR Green, from 
PPAR-γ LBD/ fluormone PPAR Green complex. Serial dilutions of each test molecule 
were prepared in DMSO. The recombinant PPAR-γ LBD (1.1 pM) was pre-incubated with 
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PPAR Green (2.5 nM) in screening buffer. After the pre-incubation, the test and PPAR-γ 
LBD/ Fluormone ligand complex solution were added into 384-well plate to produce a 
final volume of 40 μL per well. The reaction was incubated at room temperature for 2 hrs 
and polarization values were measured by using fluorescence microplate reader, Polarion 
(Tecan Research, Triangle Park, NC) with excitation wavelength 495 nm and emission 
wavelength 535 nm. Fluorescent polarization is measured in mP, a polarization unit. The 
formation of PPAR-γ LBD/ Fluormone ligand complex results in highest mP value and is 
considered as 0 % inhibition value. Hence mP value and % inhibition value are inversely 
proportional to each other. Addition of ligand to PPAR-γ LBD/ Fluormone ligand complex 
results in lower mP value and higher % inhibition values. The polarization value versus 
test compound concentration curves was analyzed by Sigma Plot software to generate IC-
50 values.  
For the intensities, the actual polarization values P (in mP values) were calculated by 
using the following formula: 
 
   P =   I║ - I ┴ / I ║+ I ┴ 
 
Where P is polarization unit, we measure polarization in mP values.  
I ║ = intensity parallel. 
I ┴ = intensity perpendicular. 
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5. Structural studies of PPAR-γ LBD in complex with PPAR-γ receptor 
modulators. 
X-ray crystallography was used to elucidate the binding modes of these synthesized 
compounds to PPAR-γ LBD. Hanging drop vapor diffusion method (shown in Figure 10) 
was used for the crystallization experiments. In the experiment, a droplet of purified 
protein, buffer and precipitant is allowed to equilibrate with a larger reservoir containing 
similar buffer and precipitant in higher concentrations.  
 
 
 
Figure 10. Protein crystallization: Hanging drop vapor diffusion method. Reservoir solution (blue) usually 
contains buffer and precipitant. Protein solution (red) contains the same compounds, but in lower 
concentrations. The protein solution may also contain trace metals or ions necessary for precipitation of 
particular proteins. 88 
 
 
A. Crystallization of Complex 
Crystallization of PPAR-γ LBD with various active compounds was carried out using 
excess of the ligand. Rosiglitazone, compound A and B were dissolved in dimethyl 
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sulfoxide (DMSO), and were added to the protein (15 mg/mL) solution at a 10:1 molar 
excess to encourage complete binding, and then incubated on ice for 1 hour prior to 
crystallization trials. Initial crystallization trials for the His-tagged PPAR-γ LBD in 
complex with the ligands were conducted using the Crystal screening kit I and II (Hampton 
Research) at 4°C, 15°C and room temperature (25°C). We obtained micro-crystals in 
previously established crystal conditions as shown below.62, 89, 90  
1.4 M Sodium Citrate (pH 5.6), 100 mM HEPES (pH 7.5). 
1. 1.4 M Sodium Citrate (pH 5.6), 20 mM tris HCl (pH 8.0). 
2. 4.0 M Sodium Formate. 
Following, we optimized these conditions to obtain X-ray quality crystals. First, we 
optimized the condition 1 above. The crystallization drop was set up using protein (15 
mg/ml in 50mM NaCl, 25 mM Tris-HCl, pH 8.0, 5mM DTT), and a reservoir solution of 
1.0 - 1.5 M Sodium Citrate (pH 5.6), 100 mM HEPES (pH 7.5).  
The crystallization condition 2 was also optimized by setting up crystal drop with 
varying reservoir solution concentrations from 0.8 M – 1.6 M Sodium Citrate (pH 5.6), 20 
mM tris HCl (pH 8.0), at 4˚ C and also at 20˚C. The protein concentration was also varied.  
The 3rd crystallization condition which showed the most encouraging results was also 
modified. The crystal drop contains 10 mg/ml protein concentration with reservoir solution 
consisting of PEG 20,000 (10% - 30%), 0.1 M MES, at 4˚C and 15˚C. 
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{CHAPTER III Results and Discussion} 
 
 
1.   Expression and Purification of PPAR-γ LBD. 
The protein was first expressed and purified as the Glutathione S Transferase-tagged 
(GST-tagged) fusion protein in order to aid in purification. GST was originally selected as 
a fusion moiety because of several desirable properties. First and foremost, when expressed 
in bacteria alone, or in fusion, GST is not sequestered in inclusion bodies. Second, GST 
can be affinity purified without denaturation because it binds to immobilized glutathione, 
which provides the basis for simple purification.  
To make the recombinant protein, the pGEX-4T1 vector with fused GST was expressed in 
E. coli Rosetta (DE3) cells.  The protein was precipitated using ammonium sulfate 
precipitations (up to 65%). Ammonium sulfate precipitated only PPAR-γ, which ensured 
the elimination of intrinsic E.coli PK from the protein mixture. The precipitated fraction 
was dissolved in 1 X PBS, pH 7.4 and 1 mM DTT containing 1 mM phenylmethylsulfonyl 
fluoride and also dialyzed overnight against the same buffer. The dialyzed protein was then 
loaded onto the previously equilibrated GST-column with 1 X PBS for purification. After 
washing with the 2 column volume 1 X PBS, the GST moiety was removed by digesting 
the fusion protein with the help of thrombin (Pharmacia) on the column. Then the cleaved 
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PPAR-γ LBD was eluted with the help of elution buffer. The results of PPAR-γ expression 
and purification are shown in Table 2. The protein yield was 5mg/L determined using 
Bradford assay. The purified enzyme also showed activity in the subsequent PPAR-γ LBD 
fluorescent assay. SDS PAGE gel in Figure 11 showed a good protein expression, however 
the purified protein still contained contaminants. Subsequently, the impure fraction was 
further purified using SEPHADEX 200 column, which did not help to separate the impure 
fraction from the pure protein fraction. Thus, the use of GST for making the protein was 
not very successful, as the quantities and purity of the PPAR-γ LBD obtained at 32 KDa 
were minimal. The process was also cumbersome and expensive.  
 To overcome this, we decided to use a different vector, pET28a (+) with His-tag 
and an alternate method of purification. First, the PPAR-γ LBD cloned in pET28a (+) 
plasmid (Novagen) was obtained from our Brazilian collaborators, Dr. Polikarpov and 
colleagues, and transferred to competent Rossetta cells (Strat-agene). The attached N-
terminal His-tag allowed PPAR-γ LBD’s to be purified by a single step Ni-NTA column 
chromatography. Using this approach, the yield of pure PPAR-γ LBD improved 
significantly up to 3-fold, typically 15 mg/L. Figure 12 shows the SDS- PAGE gel of the 
purified enzyme. Thus expression of the protein in Rosetta cells with the attached His-tag 
represents a new simple method providing improved yield for the expression and 
purification of PPAR-γ LBD.   
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Figure 11. 10% SDS-PAGE gel of PPAR-γ LBD protein purified using the procedure recommended by 
manufacturer (Amersham Pharmacia Biotech). Three fractions of protein were run in parallel with molecular 
mass standards. Lanes (1) Protein standard (Fermentas), (2) After cell brake GST- bound PPAR-γ LBD, (3) 
After ammonium sulfate GST- bound PPAR-γ LBD, (4) protein elution PPAR-γ LBD 1, (5), (6) and (7)  are 
protein elutions 2, 3 and 4 respectively.   
 
Figure 12. 10% SDS-PAGE gel of PPAR-γ LBD purified protein. Lanes (1) Protein standard (Fermentas), 
(2) and (4) are washing, (3) and (5) show varying concentrations of PPAR-γ LBD with attached His tag. 
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Table 2. Yield of PPAR-γ LBD protein with two different expression vectors. 
 
 
 
 
 
2. Molecular Modeling to Design PPAR-γ Receptor Modulators. 
Our aim was to use the structural features and binding mode of Rosiglitazone as a 
starting point to design novel PPAR-γ agonists. A visual analysis of the binding of 
Rosiglitazone suggests two possible structural modifications; first to the ether linkage and 
second to the hydrophobic side chain. This culminated into two possible classes of 
compounds, type-I and type-II compounds. Using SYBYL 7.3, representative molecules of 
these two classes (compound A from type-I and B from type-II) were built and energy 
minimized. These compounds were manually docked into PPAR-γ LBD (PDB code 
2PRG) using TOM and/or COOT. Minimization of the protein residues around the docked 
compounds using SYBYL 7.3 yielded several binding orientations. Unexpectedly, none of 
the binding orientations with high HINT scores corresponded to the crystallographically 
bound Rosiglitazone’s orientation. As a control, we also energy minimized the 
crystallographically bound Rosiglitazone (Figure 13) using SYBYL 7.3, and also 
unexpectedly the best binding orientation was not consistent with the crystallographically 
bound orientation. Based on this, we decided to use the manually fit putative compounds 
Method Yield (mg/L) 
pGEX-4T1 + GST 5 
pET 28a (+) + His-tag 15 
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based on Rosiglitazone binding for design purpose. Figure 14-17 show hypothetical 
binding of our designed type-I and type-II compounds to the PPAR-γ LBD.   
As shown in Figure 14 and 15, the thiazolidinedione rings of both compound A and 
Rosiglitazone occupy similar position. Like Rosiglitazone the two oxygen atoms of 
thiazolidinedione ring of compound A are capable of making hydrogen-bond interactions 
with His323 and His449. Secondly, the newly introduced carbonyl oxygen of the amide 
linkage in compound A is capable of making additional hydrogen-bond interaction with 
Cys285. Thirdly, the hydrophobic chain was positioned in PPAR-γ LBD binding pocket in 
the same manner as Rosiglitazone. 
In the type-II compounds, in addition to the described interactions observed for 
Rosiglitazone, the amide oxygen can also make hydrogen-bond interaction with Cys285. 
Also, the increased length of the hydrophobic side chain could make hydrophobic 
interactions with Ile281, Met348, Ile341 and Arg288. Our hypothesis is that the type-I and 
-II compounds will have higher affinity to the PPAR-γ LBD because of the additional 
hydrogen-bond and/or hydrophobic interactions with the protein.   
 
 
 
 
 
 
 
  
Figure 13. Rosiglitazone in
46
 
 
 
 
 
 
 crystal structu
 
 
re with PPAR-γ LBD. 
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Figure 14. Proposed binding mode of Compound A (type-I compound) docked manually in PPAR-γ LBD. 
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Figure 15. Proposed binding mode of compound A (type-I compound) in the PPAR-γ LBD complex. 
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 Figure 16. Proposed binding mode of compound B (type-II compound) docked manually in PPAR-
γ LBD. 
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Figure 17. Proposed binding mode of compound B (type-II compound) in the PPAR-γ LBD complex. 
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3. Synthesis of Potential PPAR-γ Receptor Modulators. 
The whole synthesis was divided into three schemes. In scheme 1 we synthesized 4, 
which would serve as precursor to scheme 2 and 3 for synthesis of both classes of 
compounds.  
A. Intermediates 
For synthesis of 4, a two step approach was adopted, first by mixing the commercially 
available starting core compound, 1 and 2, in the presence of piperidine and acetic acid in 
toluene under stirring condition, for 16-18 hrs at room temperature, 3, was obtained.  In the 
second step of scheme 1, we reduced the nitro compound to amine. To a stirring solution 
of 3 in ethanol, we added tin (II) chloride and the mixture heated to reflux for 2-3 hours, to 
obtain 4. 
B. Synthesis of type-I compounds: 
In scheme 2, the type-I compounds were synthesized by using 4 as one of the two 
reactants. Synthesis of five type-I compounds were attempted using two different 
approaches, however we were only successful in synthesizing two of the compounds, 
including A and D. For synthesis of compound A, to a mixture of 4 and triethylamine in 
dichloromethane at 0° C, in presence of nitrogen, hydrocinnamoyl chloride or 5 was added 
dropwise. 
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Scheme 1:
 
 
After stirring at the same temperature for ten minutes, the mixture was further stirred at 
room temperature for 2 hr, to obtain compound A. To a mixture of 4 and 6, in DMF, in 
presence of nitrogen at room temperature, HOBt and DEC, were added and the mixture 
stirred overnight, to obtain compound D.  
Along with above synthesized compounds shown in scheme 2, synthesis of three more 
type-I compounds G, H, I, was tried, shown in scheme 2. A similar sequence to that 
described in scheme 2 for the synthesis of type-I compound D was followed. Although 
TLC showed formation of a new entity, NMR analyses for these three compounds were not 
consistent with the structures shown below.  
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C.  Synthesis of type-II compounds: 
Synthesis of type-II compounds as shown in scheme 3 followed similar sequence as 
described in scheme 2 for the synthesis of type-I compound D. For synthesis of B, DMF 
and THF was added to a mixture of 4 and 7, under nitrogen at room temperature, along 
with HOBt and DEC and stirred overnight. For synthesis of C and F same reaction 
sequence was followed as shown in scheme 3. 
We also carried out the synthesis of two other type-II compounds J and K by following 
similar sequence we used in synthesis of B, but was unsuccessful as shown in scheme 3. 
The reaction product precipitated out, and the crude material was not soluble in any 
solvent. 
In conclusion, we have been able to synthesize five compounds, A, B, C, D and F out 
of ten that we designed. Synthesis of the other five compounds, G, H, I, J and K are 
planned in future using alternate synthetic schemes. 
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4. Functional Studies to Determine the Binding Affinity of PPAR-γ Receptor 
Modulators. 
Fluorescent-based competitive binding assay was used to find out whether the 
synthesized compounds bind to PPAR-γ LBD, as well as their binding affinities. Parallel 
experiments with Rosiglitazone and Troglitazone in our lab were also performed. If tested 
compound binds to PPAR-γ LBD, it should competitively displace the Fluormone ligand 
from the PPAR-γ-LBD/Fluormone ligand complex resulting in a low polarization value. 
Non-competitors will not displace the Fluormone ligand from the complex, so the 
polarization value remains high. The shift in polarization value in the presence of test 
compounds is used to determine relative affinity of the test compounds for the PPAR-γ 
LBD. 
Table 3 shows the competitive inhibition of the Fluormone ligand by Rosiglitazone, 
Troglitazone, compounds A, B, C, D, and F. Type-I compounds, A and D shows 74% and 
54% inhibition respectively, as compared to 89 and 99% for Rosiglitazone and 
Troglitazone, respectively. Compound A has IC-50 value of 344 μM, which translates to a 
~1900-fold lower affinity compared to Rosiglitazone (IC-50 value 0.178 μM). The IC-50 
of compound D was not determined but we expect to behave similarly as A. Type-II 
compounds, B, C and F show 98%, 73% and 78% inhibition respectively as compared to 
89% of Rosiglitazone. Compound B shows a significant binding affinity to PPAR-γ LBD, 
as evidenced by an IC-50 value of 1.3 μM, which is ~ 7-fold lower than Rosiglitazone. The 
IC-50s for the rest of the other compounds were not determined, however based on the % 
inhibition we speculate that none of them would exhibit higher potency than compound B. 
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It seems that type-II compounds may be more potent than type-I compounds. Most 
likely, the extra hydrophobic interactions made by type-II compounds with the residues 
Ile281, Met348, Ile341 and Arg288 in the PPAR-γ LBD increase their binding affinity to 
LBD compared to the type-I compounds.  
 
Table 3.  The % inhibition and IC-50 values by using Fluorescent Polarization Assay. 
 
 
 
 
 
 
 
                         
*Compounds used at 25 μM concentration. 
 
Our designed compounds were hypothesized to have higher affinity to PPAR-γ LBD 
than Rosiglitazone due to the proposed additional hydrogen-bond interaction with Cys285 
and/or hydrophobic interactions with the protein. However, they still show significantly 
lower affinity to the protein compared to Rosiglitazone. As shown in Figure 8, there is a 
double bond between the thiazolidinedione ring and the benzene ring of the core structure 
of our compounds, which is a single bond in Rosiglitazone. Thus, the thiazolidinedione 
ring in Rosiglitazone can easily rotate in the binding pocket, which is unlikely with our 
S.N.  Compound  % inhibition*  IC50(μM)  
1.  Rosiglitazone 89 0.178 
2.  Troglitazone 99 — 
3.  Compound A 74 344 
4.  Compound B 98 1.30 
5. Compound C 73 — 
6. Compound D 54 — 
7. Compound F 78 — 
8.  TDD4-73 90 9.85 
9.  TDD4-84 32 780 
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compounds. We note that the two hydrogen-bond interactions between the two carbonyl 
oxygens of thiazolidinedione ring and His323 and His449 are the most important for 
binding. Therefore, it is most likely that Rosiglitazone with a flexible thiazolidinedione 
ring can easily bind to make optimal interactions with both His323 and His449. This is 
unlikely in our compounds, where the ring is rigid and fixed at one orientation. We are 
currently synthesizing analogs of our compounds with a single bond between the ring and 
the benzene. Our hypothesis is that these compounds will result in better binding affinity. 
 
5. Structural Studies of PPAR-γ LBD in Complex with PPAR-γ Receptor 
Modulators. 
Structure-based drug design is one of the most logical approaches applied in drug 
discovery. It integrates information from several fields, such as X-ray crystallography, 
molecular modeling, synthetic organic chemistry, quantitative structure-activity 
relationship (QSAR) studies, and biological evaluation to identify new lead molecules that 
can interact specifically with the target protein structure. This is a cyclic procedure that 
refines each stage of discovery. This structural information obtained from X-ray 
crystallography enables design of new molecules or ligands, and eventually drugs that 
interfere with the binding of natural ligands to the proteins and consequently alter their 
biological function.91 
X-ray crystallographic study was thus attempted in order to determine the binding mode of 
our compounds with the PPAR-γ LBD. Crystallization experiments were conducted in the 
absence and presence of Rosiglitazone, type-I and -II compounds. Initially crystallization 
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conditions for the His-tagged PPAR-γ LBD complex, were tried using the crystal screening 
kit I and II (Hampton Research) at 20°C. Several crystallization conditions were then 
optimized further by fine griding around the initial conditions. Also, previously published 
crystallization conditions were used for crystallizing the complex. None of these 
experiments yielded X-ray quality crystals, and thus we have been unable to determine the 
co-crystal structures of these compounds with PPAR-γ LBD. 
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{CHAPTER 3 Summary and Conclusion} 
 
 
 At present, there are two marketed TZDs, Rosiglitazone and Pioglitazone, currently 
being used as first line treatment of type-II diabetes. There has been report of serious side 
effect for Rosiglitazone. A review of the studies of Rosiglitazone led the FDA to conclude 
that the medication might increase the risk of heart attacks and angina, but it’s not clear 
what the cause is, but there are speculations that this could be due to Rosiglitazone 
metabolites. The drug is still being used but with a BOXED warning. 
The development of new type-II diabetes drug that work similarly as Rosiglitazone but 
with less side effect and possibly with increased potency is much needed and very urgent. 
The main goal of the study is to develop a potential TZD agonist with improved activity 
and minimal side effects. In this study, PPAR-γ LBD was purified with simple and 
efficient method and also resulted in significant yield. Molecular modeling studies helped 
in identification of potential PPAR-γ agonists, which were synthesized. These compounds 
were designed to make additional hydrogen-bond and/or hydrophobic interaction with the 
protein. Our hypothesis is that these additional binding will lead to increase affinity and 
perhaps better agonist. For the type-I compounds, containing thaizolidinedione ring and 
carbonyl oxygen of the amide bond, their binding affinity were found to be significantly 
lower than Rosiglitazone. Type-II compounds have additional hydrophobic ring attached 
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with different functional group on it. The binding affinity of these compounds is relatively 
higher and better than type-I compounds but still significantly lower than Rosiglitazone. 
This unexpected difference in binding affinity between Rosiglitazone and both type-I and 
type-II compounds is most probably due to the fact that thaizolidinedione ring in 
Rosiglitazone can easily rotate to make optimal interactions with the protein residues 
His323 and His449, which are known to be very important for binding affinity and 
agonistic activity. This is not the case in our compounds where the double bond between 
the thaizolidinedione ring and the benzene makes the thaizolidinedione ring unable to 
rotate and perhaps make optimal contact with the residues His323 and His449.  Our 
collaborators from The Scripps Research Institute (Scripps Florida) are currently testing 
our compounds for their agonistic activity. We are also synthesizing analogs of these 
compounds with flexible thaizolidinedione ring system. To find out the important 
interactions between PPAR-γ LBD and synthesized compounds, crystallization studies 
were attempted but failed. Crystallization attempts are ongoing in order to solve the PPAR-
γ LBD structure in complex with our ligands. 
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